Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Design and synthesis of tricyclic cores for kinase inhibition.

Van Epps S, Fiamengo B, Edmunds J, Ericsson A, Frank K, Friedman M, George D, George J, Goedken E, Kotecki B, Martinez G, Merta P, Morytko M, Shekhar S, Skinner B, Stewart K, Voss J, Wallace G, Wang L, Wang L, Wishart N.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):693-8. doi: 10.1016/j.bmcl.2012.11.108. Epub 2012 Dec 5.

PMID:
23265875
2.

Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.

Patnaik S, Stevens KL, Gerding R, Deanda F, Shotwell JB, Tang J, Hamajima T, Nakamura H, Leesnitzer MA, Hassell AM, Shewchuck LM, Kumar R, Lei H, Chamberlain SD.

Bioorg Med Chem Lett. 2009 Jun 1;19(11):3136-40. doi: 10.1016/j.bmcl.2008.12.110. Epub 2009 Jan 6.

PMID:
19394223
3.

Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.

Song X, Chen W, Lin L, Ruiz CH, Cameron MD, Duckett DR, Kamenecka TM.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7072-5. doi: 10.1016/j.bmcl.2011.09.090. Epub 2011 Sep 29.

PMID:
22004719
4.

Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.

Pastor J, Oyarzabal J, Saluste G, Alvarez RM, Rivero V, Ramos F, Cendón E, Blanco-Aparicio C, Ajenjo N, Cebriá A, Albarrán MI, Cebrián D, Corrionero A, Fominaya J, Montoya G, Mazzorana M.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1591-7. doi: 10.1016/j.bmcl.2011.12.130. Epub 2012 Jan 5.

PMID:
22266039
5.

Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.

Han SY, Choi JW, Yang J, Chae CH, Lee J, Jung H, Lee K, Ha JD, Kim HR, Cho SY.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2837-42. doi: 10.1016/j.bmcl.2012.02.073. Epub 2012 Mar 7.

PMID:
22450128
6.

2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.

Lin H, Yamashita DS, Zeng J, Xie R, Verma S, Luengo JI, Rhodes N, Zhang S, Robell KA, Choudhry AE, Lai Z, Kumar R, Minthorn EA, Brown KK, Heerding DA.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. doi: 10.1016/j.bmcl.2009.11.060. Epub 2009 Nov 20.

PMID:
20005102
7.

Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.

Koch P, Jahns H, Schattel V, Goettert M, Laufer S.

J Med Chem. 2010 Feb 11;53(3):1128-37. doi: 10.1021/jm901392x.

PMID:
20078117
8.

Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.

Saleem RS, Lansdell TA, Tepe JJ.

Bioorg Med Chem. 2012 Feb 15;20(4):1475-81. doi: 10.1016/j.bmc.2011.12.054. Epub 2012 Jan 11.

PMID:
22285028
9.

In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.

Chen HH, Namil A, Severns B, Ward J, Kelly C, Drace C, McLaughlin MA, Yacoub S, Li B, Patil R, Sharif N, Hellberg MR, Rusinko A, Pang IH, Combrink KD.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1875-9. doi: 10.1016/j.bmcl.2014.03.017. Epub 2014 Mar 19.

PMID:
24684843
10.

Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.

Wallace MB, Adams ME, Kanouni T, Mol CD, Dougan DR, Feher VA, O'Connell SM, Shi L, Halkowycz P, Dong Q.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4156-8. doi: 10.1016/j.bmcl.2010.05.058. Epub 2010 May 20.

PMID:
20621728
11.

Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.

Friedman M, Frank KE, Aguirre A, Argiriadi MA, Davis H, Edmunds JJ, George DM, George JS, Goedken E, Fiamengo B, Hyland D, Li B, Murtaza A, Morytko M, Somal G, Stewart K, Tarcsa E, Van Epps S, Voss J, Wang L, Woller K, Wishart N.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4399-404. doi: 10.1016/j.bmcl.2015.09.020. Epub 2015 Sep 8.

PMID:
26372653
12.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Labadie S, Dragovich PS, Barrett K, Blair WS, Bergeron P, Chang C, Deshmukh G, Eigenbrot C, Ghilardi N, Gibbons P, Hurley CA, Johnson A, Kenny JR, Kohli PB, Kulagowski JJ, Liimatta M, Lupardus PJ, Mendonca R, Murray JM, Pulk R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward S, Zak M.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7627-33. doi: 10.1016/j.bmcl.2012.10.008. Epub 2012 Oct 11.

PMID:
23107482
13.

Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors.

Burdick DJ, Wang S, Heise C, Pan B, Drummond J, Yin J, Goeser L, Magnuson S, Blaney J, Moffat J, Wang W, Chen H.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4728-32. doi: 10.1016/j.bmcl.2015.08.048. Epub 2015 Aug 22.

PMID:
26338362
14.

Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.

Kassis P, Brzeszcz J, Bénéteau V, Lozach O, Meijer L, Le Guével R, Guillouzo C, Lewiński K, Bourg S, Colliandre L, Routier S, Mérour JY.

Eur J Med Chem. 2011 Nov;46(11):5416-34. doi: 10.1016/j.ejmech.2011.08.048. Epub 2011 Sep 8.

PMID:
21944287
15.

Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.

Shim J, Eid C, Lee J, Liu E, Chaudhary D, Boschelli DH.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6575-7. doi: 10.1016/j.bmcl.2009.10.031. Epub 2009 Oct 13.

PMID:
19854645
16.

Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.

Terao Y, Suzuki H, Yoshikawa M, Yashiro H, Takekawa S, Fujitani Y, Okada K, Inoue Y, Yamamoto Y, Nakagawa H, Yao S, Kawamoto T, Uchikawa O.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9. doi: 10.1016/j.bmcl.2012.10.084. Epub 2012 Oct 23.

PMID:
23147077
17.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.

Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB.

Bioorg Med Chem Lett. 2014 Jun 15;24(12):2635-9. doi: 10.1016/j.bmcl.2014.04.068. Epub 2014 Apr 29.

PMID:
24813737
18.

Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors.

Le Corre L, Girard AL, Aubertin J, Radvanyi F, Benoist-Lasselin C, Jonquoy A, Mugniery E, Legeai-Mallet L, Busca P, Le Merrer Y.

Org Biomol Chem. 2010 May 7;8(9):2164-73. doi: 10.1039/b923882d. Epub 2010 Mar 11.

PMID:
20401393
19.

Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines.

Guillon J, Grellier P, Labaied M, Sonnet P, Léger JM, Déprez-Poulain R, Forfar-Bares I, Dallemagne P, Lemaître N, Péhourcq F, Rochette J, Sergheraert C, Jarry C.

J Med Chem. 2004 Apr 8;47(8):1997-2009.

PMID:
15055999
20.

Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.

Zeng H, Belanger DB, Curran PJ, Shipps GW Jr, Miao H, Bracken JB, Arshad Siddiqui M, Malkowski M, Wang Y.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5. doi: 10.1016/j.bmcl.2011.07.101. Epub 2011 Aug 3.

PMID:
21855335
Items per page

Supplemental Content

Write to the Help Desk